APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripherally Acting Anti-Obesity Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Peripherally Acting Anti-Obesity Drug Industry Research Report 2026

20 December 2025120 pages

Choose your research edition.

Industry ResearchPeripherally Acting Anti-Obesity Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peripherally Acting Anti-Obesity Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Peripherally Acting Anti-Obesity Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Peripherally Acting Anti-Obesity Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Peripherally Acting Anti-Obesity Drug include Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, Vivus LLC., Rhythm Pharmaceuticals, KVK Tech Inc., Gelesis Holdings, Currax Pharmaceuticals LLC and CHEPLAPHARM Arzneimittel GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Peripherally Acting Anti-Obesity Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Peripherally Acting Anti-Obesity Drug Market by Company

Novo Nordisk A/S

Pfizer Inc.

GlaxoSmithKline plc

Vivus LLC.

Rhythm Pharmaceuticals

KVK Tech Inc.

Gelesis Holdings

Currax Pharmaceuticals LLC

CHEPLAPHARM Arzneimittel GmbH

Boehringer Ingelheim International GmbH

Peripherally Acting Anti-Obesity Drug Segment by Type

Prescription Drugs

Non-prescription Drugs

Peripherally Acting Anti-Obesity Drug Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Peripherally Acting Anti-Obesity Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripherally Acting Anti-Obesity Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripherally Acting Anti-Obesity Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripherally Acting Anti-Obesity Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Peripherally Acting Anti-Obesity Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Peripherally Acting Anti-Obesity Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peripherally Acting Anti-Obesity Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Peripherally Acting Anti-Obesity Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Peripherally Acting Anti-Obesity Drug Revenue of Manufacturers (2021-2026) Table 9. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Peripherally Acting Anti-Obesity Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Peripherally Acting Anti-Obesity Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Product Type & Application Table 14. Global Peripherally Acting Anti-Obesity Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Peripherally Acting Anti-Obesity Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novo Nordisk A/S Company Information Table 19. Novo Nordisk A/S Business Overview Table 20. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio Table 22. Novo Nordisk A/S Recent Developments Table 23. Pfizer Inc. Company Information Table 24. Pfizer Inc. Business Overview Table 25. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 27. Pfizer Inc. Recent Developments Table 28. GlaxoSmithKline plc Company Information Table 29. GlaxoSmithKline plc Business Overview Table 30. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio Table 32. GlaxoSmithKline plc Recent Developments Table 33. Vivus LLC. Company Information Table 34. Vivus LLC. Business Overview Table 35. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 37. Vivus LLC. Recent Developments Table 38. Rhythm Pharmaceuticals Company Information Table 39. Rhythm Pharmaceuticals Business Overview Table 40. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio Table 42. Rhythm Pharmaceuticals Recent Developments Table 43. KVK Tech Inc. Company Information Table 44. KVK Tech Inc. Business Overview Table 45. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 47. KVK Tech Inc. Recent Developments Table 48. Gelesis Holdings Company Information Table 49. Gelesis Holdings Business Overview Table 50. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio Table 52. Gelesis Holdings Recent Developments Table 53. Currax Pharmaceuticals LLC Company Information Table 54. Currax Pharmaceuticals LLC Business Overview Table 55. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio Table 57. Currax Pharmaceuticals LLC Recent Developments Table 58. CHEPLAPHARM Arzneimittel GmbH Company Information Table 59. CHEPLAPHARM Arzneimittel GmbH Business Overview Table 60. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 62. CHEPLAPHARM Arzneimittel GmbH Recent Developments Table 63. Boehringer Ingelheim International GmbH Company Information Table 64. Boehringer Ingelheim International GmbH Business Overview Table 65. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 67. Boehringer Ingelheim International GmbH Recent Developments Table 68. Global Peripherally Acting Anti-Obesity Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (k units) Table 70. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2026) Table 71. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032) & (k units) Table 72. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2027-2032) Table 73. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2026) Table 75. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2027-2032) Table 77. North America Peripherally Acting Anti-Obesity Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 79. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 80. North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 84. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 85. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 89. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 90. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Peripherally Acting Anti-Obesity Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 94. South America Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 95. South America Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Peripherally Acting Anti-Obesity Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 99. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 100. Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 103. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 104. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2026) Table 105. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2027-2032) Table 106. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2026) Table 109. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2027-2032) Table 110. Global Peripherally Acting Anti-Obesity Drug Price by Type (2021-2026) & (US$/unit) Table 111. Global Peripherally Acting Anti-Obesity Drug Price by Type (2027-2032) & (US$/unit) Table 112. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 113. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 114. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2026) Table 115. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2027-2032) Table 116. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2026) Table 119. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2027-2032) Table 120. Global Peripherally Acting Anti-Obesity Drug Price by Application (2021-2026) & (US$/unit) Table 121. Global Peripherally Acting Anti-Obesity Drug Price by Application (2027-2032) & (US$/unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Peripherally Acting Anti-Obesity Drug Distributors List Table 125. Peripherally Acting Anti-Obesity Drug Customers List Table 126. Peripherally Acting Anti-Obesity Drug Industry Trends Table 127. Peripherally Acting Anti-Obesity Drug Industry Drivers Table 128. Peripherally Acting Anti-Obesity Drug Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Peripherally Acting Anti-Obesity Drug Product Image Figure 5. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Peripherally Acting Anti-Obesity Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032) & (k units) Figure 8. Global Peripherally Acting Anti-Obesity Drug Average Price (US$/unit) & (2021-2032) Figure 9. Prescription Drugs Product Image Figure 10. Non-prescription Drugs Product Image Figure 11. Online Pharmacies Product Image Figure 12. Hospital Pharmacies Product Image Figure 13. Retail Pharmacies Product Image Figure 14. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peripherally Acting Anti-Obesity Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Peripherally Acting Anti-Obesity Drug Sales by Region in 2025 Figure 20. Global Peripherally Acting Anti-Obesity Drug Revenue by Region in 2025 Figure 21. North America Peripherally Acting Anti-Obesity Drug Market Size by Country in 2025 Figure 22. North America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 23. North America Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Peripherally Acting Anti-Obesity Drug Market Size by Country in 2025 Figure 28. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country in 2025 Figure 41. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2021-2032) Figure 43. China Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Peripherally Acting Anti-Obesity Drug Market Size by Country in 2025 Figure 52. South America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 53. South America Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032) Figure 66. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Peripherally Acting Anti-Obesity Drug Price (US$/unit) by Type (2021-2032) Figure 68. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032) Figure 69. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Peripherally Acting Anti-Obesity Drug Price (US$/unit) by Application (2021-2032) Figure 71. Peripherally Acting Anti-Obesity Drug Value Chain Figure 72. Peripherally Acting Anti-Obesity Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Prescription Drugs
  • Non-prescription Drugs
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Vivus LLC.
  • Rhythm Pharmaceuticals
  • KVK Tech Inc.
  • Gelesis Holdings
  • Currax Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Peripherally Acting Anti-Obesity Drug Market Size (2021-2032)
  4. 2.2.2 Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032)
  5. 2.2.3 Global Peripherally Acting Anti-Obesity Drug Market Average Price (2021-2032)
  6. 2.3 Peripherally Acting Anti-Obesity Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Prescription Drugs
  9. 2.3.3 Non-prescription Drugs
  10. 2.4 Peripherally Acting Anti-Obesity Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Online Pharmacies
  13. 2.4.3 Hospital Pharmacies
  14. 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Peripherally Acting Anti-Obesity Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Peripherally Acting Anti-Obesity Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Peripherally Acting Anti-Obesity Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Peripherally Acting Anti-Obesity Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Peripherally Acting Anti-Obesity Drug, Established Date
  9. 3.9 Global Peripherally Acting Anti-Obesity Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novo Nordisk A/S
  2. 4.1.1 Novo Nordisk A/S Company Information
  3. 4.1.2 Novo Nordisk A/S Business Overview
  4. 4.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
  6. 4.1.5 Novo Nordisk A/S Recent Developments
  7. 4.2 Pfizer Inc.
  8. 4.2.1 Pfizer Inc. Company Information
  9. 4.2.2 Pfizer Inc. Business Overview
  10. 4.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  12. 4.2.5 Pfizer Inc. Recent Developments
  13. 4.3 GlaxoSmithKline plc
  14. 4.3.1 GlaxoSmithKline plc Company Information
  15. 4.3.2 GlaxoSmithKline plc Business Overview
  16. 4.3.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
  18. 4.3.5 GlaxoSmithKline plc Recent Developments
  19. 4.4 Vivus LLC.
  20. 4.4.1 Vivus LLC. Company Information
  21. 4.4.2 Vivus LLC. Business Overview
  22. 4.4.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
  24. 4.4.5 Vivus LLC. Recent Developments
  25. 4.5 Rhythm Pharmaceuticals
  26. 4.5.1 Rhythm Pharmaceuticals Company Information
  27. 4.5.2 Rhythm Pharmaceuticals Business Overview
  28. 4.5.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
  30. 4.5.5 Rhythm Pharmaceuticals Recent Developments
  31. 4.6 KVK Tech Inc.
  32. 4.6.1 KVK Tech Inc. Company Information
  33. 4.6.2 KVK Tech Inc. Business Overview
  34. 4.6.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  36. 4.6.5 KVK Tech Inc. Recent Developments
  37. 4.7 Gelesis Holdings
  38. 4.7.1 Gelesis Holdings Company Information
  39. 4.7.2 Gelesis Holdings Business Overview
  40. 4.7.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
  42. 4.7.5 Gelesis Holdings Recent Developments
  43. 4.8 Currax Pharmaceuticals LLC
  44. 4.8.1 Currax Pharmaceuticals LLC Company Information
  45. 4.8.2 Currax Pharmaceuticals LLC Business Overview
  46. 4.8.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
  48. 4.8.5 Currax Pharmaceuticals LLC Recent Developments
  49. 4.9 CHEPLAPHARM Arzneimittel GmbH
  50. 4.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
  51. 4.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
  52. 4.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  54. 4.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments
  55. 4.10 Boehringer Ingelheim International GmbH
  56. 4.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 4.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 4.10.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  60. 4.10.5 Boehringer Ingelheim International GmbH Recent Developments
5 Global Peripherally Acting Anti-Obesity Drug Market Scenario by Region
  1. 5.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2027-2032
  5. 5.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2027-2032
  8. 5.4 North America Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
  9. 5.4.1 North America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
  41. 5.7.1 South America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Peripherally Acting Anti-Obesity Drug Value Chain Analysis
  2. 8.1.1 Peripherally Acting Anti-Obesity Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Peripherally Acting Anti-Obesity Drug Production Mode & Process
  5. 8.2 Peripherally Acting Anti-Obesity Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Peripherally Acting Anti-Obesity Drug Distributors
  8. 8.2.3 Peripherally Acting Anti-Obesity Drug Customers
9 Global Peripherally Acting Anti-Obesity Drug Analyzing Market Dynamics
  1. 9.1 Peripherally Acting Anti-Obesity Drug Industry Trends
  2. 9.2 Peripherally Acting Anti-Obesity Drug Industry Drivers
  3. 9.3 Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges
  4. 9.4 Peripherally Acting Anti-Obesity Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst